Belimumab for systemic lupus erythematosus

The Lancet

Volumn 377, Issue 9783, 2011, Pages 2079-2080

  Dhaun, Neeraj ^a   Kluth, David C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CREATININE; PLACEBO;

CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79959348869     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60911-2     Document Type: Letter

References (3)

1. SV Navarra, RM Guzmán, AE Gallacher for the BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 721 731
2. GK Berstsias, JE Salmon, DT Boumpas Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade Ann Rheum Dis 69 2010 1603 1611
3. D de Zeeuw, G Remuzzi, HH Parving et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 2004 2309 2320 (Pubitemid 38670018)